TG Therapeutics Sees Unusually High Options Volume (TGTX)
TG Therapeutics Inc (NASDAQ:TGTX) was the recipient of some unusual options trading activity on Friday. Stock traders purchased 698 put options on the stock. This represents an increase of 1,083% compared to the average daily volume of 59 put options.
In other news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total transaction of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 16.70% of the stock is currently owned by company insiders.
A number of large investors have recently bought and sold shares of the business. Schwab Charles Investment Management Inc. boosted its stake in shares of TG Therapeutics by 22.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 87,950 shares of the biopharmaceutical company’s stock worth $884,000 after acquiring an additional 15,900 shares during the last quarter. Rhumbline Advisers boosted its stake in shares of TG Therapeutics by 25.2% during the 2nd quarter. Rhumbline Advisers now owns 52,602 shares of the biopharmaceutical company’s stock worth $529,000 after acquiring an additional 10,585 shares during the last quarter. State of Wisconsin Investment Board purchased a new position in shares of TG Therapeutics during the 2nd quarter worth $412,000. Bank of New York Mellon Corp boosted its stake in shares of TG Therapeutics by 9.3% during the 2nd quarter. Bank of New York Mellon Corp now owns 297,176 shares of the biopharmaceutical company’s stock worth $2,987,000 after acquiring an additional 25,297 shares during the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of TG Therapeutics by 14.9% during the 2nd quarter. Legal & General Group Plc now owns 11,264 shares of the biopharmaceutical company’s stock worth $114,000 after acquiring an additional 1,463 shares during the last quarter. 50.41% of the stock is owned by institutional investors and hedge funds.
TGTX has been the subject of several analyst reports. SunTrust Banks reissued a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a research report on Tuesday, October 3rd. ValuEngine downgraded shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright reissued a “buy” rating and set a $33.00 price target (up previously from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. B. Riley initiated coverage on shares of TG Therapeutics in a research report on Friday, December 1st. They set a “buy” rating and a $21.50 price target for the company. Finally, Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.
Shares of TG Therapeutics (NASDAQ:TGTX) opened at $9.10 on Monday. TG Therapeutics has a 1 year low of $4.10 and a 1 year high of $15.35. The company has a market cap of $642.93, a P/E ratio of -4.72 and a beta of 1.30.
TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.05). TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. The company had revenue of $0.04 million during the quarter, compared to the consensus estimate of $0.04 million. equities analysts predict that TG Therapeutics will post -1.87 earnings per share for the current year.
WARNING: This story was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was stolen and republished in violation of United States & international copyright and trademark law. The legal version of this story can be read at https://www.watchlistnews.com/tg-therapeutics-sees-unusually-high-options-volume-tgtx/1798253.html.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.